Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer - PubMed (original) (raw)
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer
Phonphimon Wongthida et al. Cancer Res. 2010.
Abstract
Innate immune effector mechanisms triggered by oncolytic viruses may contribute to the clearance of both infected and uninfected tumor cells in immunocompetent murine hosts. Here, we developed an in vitro tumor cell/bone marrow coculture assay and used it to dissect innate immune sensor and effector responses to intratumoral vesicular stomatitis virus (VSV). We found that the type III IFN interleukin-28 (IL-28) was induced by viral activation of innate immune-sensing cells, acting as a key mediator of VSV-mediated virotherapy of B16ova melanomas. Using tumor variants which differentially express the IL-28 receptor, we showed that IL-28 induced by VSV within the tumor microenvironment sensitizes tumor cells to natural killer cell recognition and activation. These results revealed new insights into the immunovirological mechanisms associated with oncolytic virotherapy in immune-competent hosts. Moreover, they defined a new class of tumor-associated mutation, such as acquired loss of responsiveness to IL-28 signaling, which confers insensitivity to oncolytic virotherapy through a mechanism independent of viral replication in vitro. Lastly, the findings suggested new strategies to manipulate immune signals that may enhance viral replication, along with antitumor immune activation, and improve the efficacy of oncolytic virotherapies.
Copyright 2010 AACR.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Figures
Figure 1
VSV activates bone marrow cytotoxicity against B16ova. A, in vitro coculture between tumor cells and bone marrow cells; NAb: neutralizing anti-VSV immune serum. B, light microscopy of cocultures (from A) of B16ova cells 24 h following treatment with (i) VSV MOI 0.1 (no bone marrow), (ii) VSV+NAb (no bone marrow), (iii) bone marrow+NAb, (iv) bone marrow cells alone (no VSV or Nab), or (v) bone marrow (BM)+VSV+NAb.
Figure 2
B16(LIF) cells are insensitive to VSV-activated bone marrow cytotoxicity. A and B, B16ova or B16(LIF) cells were cocultured with C57Bl/6 bone marrow with, or without, VSV as in Fig. 1A. Cell survival was assessed by crystal violet staining (A) or MTT assay (B). C, C57Bl/6 (8 mice/group) bearing 7-d subcutaneous (s.c.) B16(LIF) (i) or B16ova (ii) tumors were injected intratumorally every 2 d (three total) with 5 × 108 pfu of heat-inactivated virus (HI) or VSV. Survival with time is shown. D, cDNA from B16ova or B16(LIF) cells was screened for IL-28R. A weak signal was detected in B16(LIF) cells with 20 additional cycles. **, P < 0.01; ***, P < 0.001; ns; non significant.
Figure 3
VSV-activated bone marrow cytotoxicity depends upon type I and III IFNs. A, B16ova cells were cocultured with bone marrow cells as in Fig. 1A, with or without anti-IL-28 antibody (15 ug/mL) upon infection with VSV. Twenty-four hours later, supernatants were harvested for viral titer and cell viability was assessed by crystal violet staining (A) and MTT assay (B). C, light microscopy of cocultures of B16ova cells with either C57Bl/6-derived bone marrow (i and iii) or bone marrow from IFN-α/βR KO mice (ii, iv, v, and vi) 48 h following treatment with VSV (MOI 0.1) +NAb (I and ii) or bone marrow+Nab (no VSV; iii and iv), or with bone marrow from IFN-α/βR KO mice +Nab (no VSV) with added IFN-α at 1 (v) or 100 (vi) U/mL. MTT assay of these results is shown in vii. D, the experiment in A was repeated with coculture of B16ova with C57Bl/6- or IFN-α/βR KO-derived bone marrow, with VSV +/− anti-IL-28 antibody. Twenty-four hours after VSV, supernatants were harvested for viral titer and cell viability was assessed by crystal violet. ***, P < 0.001.
Figure 4
GR1+ cells in bone marrow sense VSV. A, bone marrow from C57Bl/6 mice was left undepleted (none) or depleted of macrophages, NK, CD8, CD4, or GR1+ cells and cocultured with B16ova cells +/− VSV (MOI 0.1) as in Fig. 1A. Forty-eight hours after addition of VSV, supernatants were assayed for IL-28. B, C57Bl/6 (3 mice/group) bearing B16ova tumors were injected intratumorally with 5 × 108 pfu of VSV (filled column) or PBS (opened column). Tumors (i) and draining lymph node (LN; ii and iii) were harvested at times shown and analyzed for (i) neutrophils (CD11b+GR1+F4/80−), CD11b+GR1+ (ii), or plasmacytoid dendritic cells (CD11b+GR1+PDCA+; iii). Infiltrates in tumors injected intratumorally with heat-inactivated VSV as a negative control were directly comparable with those tumors treated with PBS (data not shown). TM, tumor; DC, dendritic cells. C, C57Bl/6 bone marrow was left undepleted (i) or depleted of macrophages (ii) or GR1+ cells (iii), and cocultured with B16ova with VSV (MOI, 0.1) and neutralizing anti-VSV antibody (NAb) as in Fig. 1A. Forty-eight hours after the addition of VSV, cell survival was visualized or quantified by MTT assay (D). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 5
IL-28 activates the NK recognition of B16ova. A and B, B16ova (A) or B16(LIF) (B) were cultured +/− recombinant IL-28 for 24 h and cDNA was screened for expression of NK ligands RAE, H60, and MULT-1. *, signal detected upon additional 20 cycles. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. C, NK cells were cocultured with B16ova (a–i) or B16(LIF) (a’-i’) +/− IL-28 or 48-h conditioned medium from C57Bl/6 bone marrow cells exposed to VSV (MOI, 0.1). Twenty-four hours later, supernatants were assayed for IFN-γ. D, mice (n = 8/group) bearing 4d B16ova s.c. tumors were depleted of NK cells by anti–asialo-GM-1 antibody or mock depleted (control IgG). VSV was injected intratumorally on days 7, 9, and 11. **, P < 0.01.
Figure 6
IL-28 signaling mediates the VSV therapy of B16ova tumors. A, freeze thaw lysates of in vitro cultured B16ova or B16ova infected with VSV (MOI, 0.1) 24 h previously or of 7d–established B16ova tumors from mice treated intratumorally with either PBS or VSV (5 × 108 pfu) 24 h previously were assayed for IL-28. B, C57Bl/6 mice (n = 8/group) bearing 7d–established subcutaneous B16ova tumors were injected intratumorally at days 7, 9, and 11 with 5 × 108 pfu of heat-inactivated virus (HI) or VSV along with anti–IL-28 or control antibody. C, C57Bl/6 mice (n = 8/group) bearing 7d–established B16(LIF) or B16(LIF)-IL-28R tumors were injected intratumorally with 5 × 108 pfu of heat-inactivated VSV (HI-VSV) or VSV on days 7, 9, and 11. ***, P < 0.001.
Similar articles
- VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R. Wongthida P, et al. Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19. Mol Ther. 2011. PMID: 20959810 Free PMC article. - Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R. Willmon C, et al. Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26. Mol Ther. 2011. PMID: 20978474 Free PMC article. - Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R. Galivo F, et al. Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17. Gene Ther. 2010. PMID: 20016540 Free PMC article. - VSV-tumor selective replication and protein translation.
Barber GN. Barber GN. Oncogene. 2005 Nov 21;24(52):7710-9. doi: 10.1038/sj.onc.1209042. Oncogene. 2005. PMID: 16299531 Review. - Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, Nayak D. Bishnoi S, et al. Viruses. 2018 Feb 23;10(2):90. doi: 10.3390/v10020090. Viruses. 2018. PMID: 29473868 Free PMC article. Review.
Cited by
- The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?
Franks ML, An JH, Leavenworth JW. Franks ML, et al. Vaccines (Basel). 2024 Jun 28;12(7):721. doi: 10.3390/vaccines12070721. Vaccines (Basel). 2024. PMID: 39066359 Free PMC article. Review. - Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.
Bykov Y, Dawodu G, Javaheri A, Garcia-Sastre A, Cuadrado-Castano S. Bykov Y, et al. J Cancer Metastasis Treat. 2023;9:10. doi: 10.20517/2394-4722.2022.92. Epub 2023 Apr 4. J Cancer Metastasis Treat. 2023. PMID: 37974615 Free PMC article. - Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.
Webb MJ, Kottke T, Kendall BL, Swanson J, Uzendu C, Tonne J, Thompson J, Metko M, Moore M, Borad M, Roberts L, Diaz RM, Olin M, Borgatti A, Vile R. Webb MJ, et al. Mol Ther Oncolytics. 2023 May 22;29:129-142. doi: 10.1016/j.omto.2023.05.006. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37313455 Free PMC article. - Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research.
Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Chakraborty R, et al. Cancers (Basel). 2023 Jan 30;15(3):852. doi: 10.3390/cancers15030852. Cancers (Basel). 2023. PMID: 36765809 Free PMC article. Review. - Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.
Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N. Garmaroudi GA, et al. Oxid Med Cell Longev. 2022 Jul 22;2022:3142306. doi: 10.1155/2022/3142306. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35910836 Free PMC article. Review.
References
- Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7:781–787. - PubMed
- Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5:965–976. - PubMed
- Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12:141–161. - PubMed
- Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854–856. - PubMed
- Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008;56(Suppl 1):3–59s. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA107082/CA/NCI NIH HHS/United States
- R01 CA107082/CA/NCI NIH HHS/United States
- CA130878/CA/NCI NIH HHS/United States
- R01 CA132734/CA/NCI NIH HHS/United States
- CA132734/CA/NCI NIH HHS/United States
- R01 CA130878/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases